Artivion (AORT) Set to Announce Earnings on Monday

Artivion (NYSE:AORT) is set to announce its earnings results after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of $0.02 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, February 15th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.24. Artivion had a negative net margin of 8.67% and a positive return on equity of 3.02%. The firm had revenue of $93.67 million during the quarter, compared to the consensus estimate of $89.75 million. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Artivion Trading Up 1.8 %

Shares of NYSE AORT opened at $20.93 on Friday. Artivion has a 1-year low of $12.16 and a 1-year high of $21.90. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.85 and a quick ratio of 3.43. The business’s 50 day moving average is $20.38 and its two-hundred day moving average is $17.97. The stock has a market capitalization of $862.32 million, a P/E ratio of -27.91 and a beta of 1.66.

Wall Street Analyst Weigh In

AORT has been the topic of several analyst reports. Needham & Company LLC reissued a “buy” rating and set a $25.00 target price on shares of Artivion in a research report on Monday, April 8th. Stifel Nicolaus boosted their price objective on shares of Artivion from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 16th.

Insiders Place Their Bets

In other Artivion news, VP Andrew M. Green sold 1,462 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $20.00, for a total value of $29,240.00. Following the sale, the vice president now owns 41,121 shares in the company, valued at $822,420. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Artivion news, CAO Amy Horton sold 1,695 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $18.86, for a total transaction of $31,967.70. Following the transaction, the chief accounting officer now owns 122,345 shares of the company’s stock, valued at approximately $2,307,426.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Andrew M. Green sold 1,462 shares of the business’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $20.00, for a total transaction of $29,240.00. Following the completion of the sale, the vice president now owns 41,121 shares of the company’s stock, valued at approximately $822,420. The disclosure for this sale can be found here. Insiders sold a total of 149,952 shares of company stock valued at $2,891,627 over the last 90 days. Insiders own 8.10% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.